Literature DB >> 11148602

Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy.

K Shinoda1, S Ishida, S Kawashima, T Wakabayashi, M Uchita, T Matsuzaki, M Takayama, K Shinmura, M Yamada.   

Abstract

PURPOSE: To investigate clinical factors related to the aqueous humor levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in patients with proliferative diabetic retinopathy (PDR).
METHODS: Undiluted aqueous humor was obtained during ocular surgery from 46 eyes of 46 patients and the levels of growth factors were measured using enzyme-linked immunosorbent assays. VEGF and HGF levels were compared with the number of photocoagulation. VEGF and HGF levels in patient groups stratified according to the existence of vitreous hemorrhage, retinal detachment, and fibrovascular membrane were analyzed. And clinical parameters associated with the growth factors were determined by multiple regression analysis.
RESULTS: The levels of VEGF decreased significantly as the extent of photocoagulation increased and showed significant positive correlation with the existence of vitreous hemorrhage. There was no significant correlation between VEGF levels and the existence of fibrovascular membrane and traction retinal detachment. The levels of HGF also decreased significantly as the extent of photocoagulation increased, but increased significantly when fibrovascular membrane existed. There were no significant correlations between HGF levels and the existence of vitreous hemorrhage and traction retinal detachment. Concerning systemic conditions, each growth factor has no significant correlation with duration and type of diabetes mellitus, the treatment regimen, the control of hemoglobin A1C, and the existence of hypertension or renal dysfunction.
CONCLUSION: The therapeutic effect of panretinal photocoagulation on PDR might be partly exerted by reduction of the levels of VEGF and HGF in ocular fluid. Since the clinical parameters associated with VEGF were different from those associated with HGF, these growth factors might influence the progression of retinopathy in different ways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11148602

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Review of therapeutic advances in diabetic retinopathy.

Authors:  Chirag P Shah; Carolyn Chen
Journal:  Ther Adv Endocrinol Metab       Date:  2011-02       Impact factor: 3.565

2.  Targeting Neovascularization in Ischemic Retinopathy: Recent Advances.

Authors:  Mohamed Al-Shabrawey; Mohamed Elsherbiny; Julian Nussbaum; Amira Othman; Sylvia Megyerdi; Amany Tawfik
Journal:  Expert Rev Ophthalmol       Date:  2013-06

Review 3.  Changes in aqueous and vitreous inflammatory cytokine levels in proliferative diabetic retinopathy: a systematic review and meta-analysis.

Authors:  Ryan H Mason; Samuel A Minaker; Gabriela Lahaie Luna; Priya Bapat; Armin Farahvash; Anubhav Garg; Nishaant Bhambra; Rajeev H Muni
Journal:  Eye (Lond)       Date:  2022-06-07       Impact factor: 4.456

Review 4.  Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes.

Authors:  Alireza Lashay; Hooshang Faghihi; Ahmad Mirshahi; Hassan Khojasteh; Alireza Khodabande; Hamid Riazi-Esfahani; Fahimeh Asadi Amoli; Elias Khalili Pour; Elham Delrish
Journal:  J Ophthalmic Vis Res       Date:  2020-08-06

5.  Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema.

Authors:  Donald S Fong; Samara F Strauber; Lloyd Paul Aiello; Roy W Beck; David G Callanan; Ronald P Danis; Matthew D Davis; Stephen S Feman; Frederick Ferris; Scott M Friedman; Charles A Garcia; Adam R Glassman; Dennis P Han; Darma Le; Craig Kollman; Andreas K Lauer; Franco M Recchia; Sharon D Solomon
Journal:  Arch Ophthalmol       Date:  2007-04

Review 6.  Diabetic macular edema: New promising therapies.

Authors:  Hanan N Al Shamsi; Jluwi S Masaud; Nicola G Ghazi
Journal:  World J Diabetes       Date:  2013-12-15

7.  Relationship between vitreous and serum vascular endothelial growth factor levels, control of diabetes and microalbuminuria in proliferative diabetic retinopathy.

Authors:  Nader Baharivand; Nosratollah Zarghami; Farid Panahi; M Yazdan Dokht Ghafari; Ali Mahdavi Fard; Abbas Mohajeri
Journal:  Clin Ophthalmol       Date:  2012-01-26

8.  Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes.

Authors:  Alireza Lashay; Hamid Riazi-Esfahani; Hooshang Faghihi; Ahmad Mirshahi; Hassan Khojasteh; Alireza Khodabande; Fahimeh Asadi Amoli; Fariba Ghassemi; Fatemeh Bazvand; Elias Khalili Pour; Nazanin Ebrahimiadib; Ali Torkashvand; Elham Delrish
Journal:  J Ophthalmol       Date:  2020-07-03       Impact factor: 1.909

9.  Aqueous Humor Mediator and Cytokine Aberrations in Diabetic Retinopathy and Diabetic Macular Edema: A Systematic Review and Meta-Analysis.

Authors:  Jingyang Wu; Yifan Zhong; Song Yue; Kaibo Yang; Guisen Zhang; Lei Chen; Lei Liu
Journal:  Dis Markers       Date:  2019-11-23       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.